Tectonic Therapeutic, Inc. (TECX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$19.42-4.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TECX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-11.9) + peer(0.2*0.0) + term(0.0) → -4.15% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
today
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On November 5, 2026, Tectonic Therapeutic, Inc. announced its financial results for the third quarter ended September 30, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On August 6, 2026, Tectonic Therapeutic, Inc. announced its financial results for the second quarter ended June 30, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On February 26, 2026, Tectonic Therapeutic, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On November 6, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended September 30, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On August 7, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended June 30, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On May 8, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On March 20, 2025, Tectonic Therapeutic, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On November 7, 2024, Tectonic Therapeutic, Inc. announced its financial results for the three and nine months ended September 30, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On August 14, 2024, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended June 30, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On May 11, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months ended March 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Results of Operations and Financial Condition. On March 23, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange…
Results of Operations and Financial Condition. On November 8, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and nine months ended September 30, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Excha…
Results of Operations and Financial Condition. On August 9, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and six months ended June 30, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”…
Results of Operations and Financial Condition. On May 10, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months ended March 31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Results of Operations and Financial Condition. On March 17, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange…